Clinical Trial Update: Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation [Phase 2]

View source ↗

Summary

Phase II trial of tazemetostat in solid tumors harboring ARID1A mutations has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: Prisma Health-Upstate | Conditions: Solid Tumor, ARID1A Gene Mutation | Phase 2 | Status: TERMINATED